Congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

Hiromi Watanabe, Eiki Ichihara, Hirohisa Kano, Kiichiro Ninomiya, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We herein report a case of congestive heart failure which developed during osimertinib treatment. A 78-year-old woman presented with mild exertional dyspnea three weeks after starting osimertinib for the treatment of epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer. She was diagnosed with congestive heart failure caused by the osimertinib. In contrast to trastuzumab, a human epidermal growth factor receptor 2 (HER2) monoclonal antibody that often causes cardiac dysfunction, the causal relationship between osimertinib and cardiotoxicity has so far received little attention and thus remains unclear. However, it inhibits HER2 in addition to mutant EGFR, thereby potentially causing cardiotoxicity.

Original languageEnglish
Pages (from-to)2195-2197
Number of pages3
JournalInternal Medicine
Volume56
Issue number16
DOIs
Publication statusPublished - 2017

    Fingerprint

Keywords

  • Heart failure
  • Lung cancer
  • Osimertinib
  • T790M

ASJC Scopus subject areas

  • Internal Medicine

Cite this